Nuveen Asset Management, LLC Bio N Tech Se Transaction History

Nuveen Asset Management, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$122.57 - $153.67 $18 Million - $22.6 Million	-146,764 Reduced 47.45%	162,518 $20.2 Million
Q4 2022 Feb 14, 2023	BUY	$118.43 - $186.05 $11.9 Million - $18.8 Million	100,887 Added 48.41%	309,282 $46.5 Million
Q3 2022 Nov 14, 2022	BUY	$127.65 - $183.11 $7.14 Million - $10.2 Million	55,925 Added 36.68%	208,395 $28.1 Million
Q2 2022 Aug 15, 2022	SELL	$123.25 - $186.24 $4.63 Million - $6.99 Million	-37,530 Reduced 19.75%	152,470 $22.7 Million
Q1 2022 May 16, 2022	BUY	$126.25 - $231.85 $23.1 Million - $42.3 Million	182,634 Added 2479.42%	190,000 $32.4 Million
Q4 2021 Feb 14, 2022	SELL	$216.64 - $362.52 $39.1 Million - $65.5 Million	-180,709 Reduced 96.08%	7,366 $1.9 Million
Q3 2021 Nov 12, 2021	BUY	$205.93 - $447.23 $37.8 Million - $82 Million	183,376 Added 3902.45%	188,075 $51.3 Million
Q2 2021 Aug 16, 2021	SELL	$113.32 - $241.49 $11,105 - $23,666	-98 Reduced 2.04%	4,699 $1.05 Million
Q1 2021 May 17, 2021	BUY	$85.73 - $119.5 $411,246 - $573,241	4,797 New	4,797 $524,000

360

38.3M

2.45M

2.29M

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $30B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.